Evidence map›Paper›PMID 27385405›Full record

ArticleACS chemical neuroscience2016

Ac-Trp-DPhe(p-I)-Arg-Trp-NH2, a 250-Fold Selective Melanocortin-4 Receptor (MC4R) Antagonist over the Melanocortin-3 Receptor (MC3R), Affects Energy Homeostasis in Male and Female Mice Differently.

Cody J Lensing, Danielle N Adank, Skye R Doering, Stacey L Wilber, Amy Andreasen, Jay W Schaub, Zhimin Xiang, Carrie Haskell-Luevano

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.Biochimica et biophysica acta. Molecular basis of disease · 2017
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Cody J LensingDepartment of Medicinal Chemistry, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Danielle N AdankDepartment of Medicinal Chemistry, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Skye R DoeringDepartment of Medicinal Chemistry, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Stacey L WilberDepartment of Medicinal Chemistry, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Amy AndreasenDepartment of Pharmacodynamics, College of Pharmacy, University of Florida , Gainesville, Florida 32611, United States.
Jay W SchaubDepartment of Pharmacodynamics, College of Pharmacy, University of Florida , Gainesville, Florida 32611, United States.
Zhimin XiangDepartment of Pharmacodynamics, College of Pharmacy, University of Florida , Gainesville, Florida 32611, United States.
Carrie Haskell-LuevanoDepartment of Medicinal Chemistry, University of Minnesota , Minneapolis, Minnesota 55455, United States.
University of Minnesota · USUniversity of Florida · US

Funding

Melanocortin Selective LigandsR01DK091906 · NIDDK · UNIVERSITY OF MINNESOTA · PI HASKELL-LUEVANO, CARRIE · 2012 to 2015
$1.8M
NIDDK NIH HHS R01 DK091906
6 · The paper itself

Abstract

The melanocortin-4 receptor (MC4R) has been indicated as a therapeutic target for metabolic disorders such as anorexia, cachexia, and obesity. The current study investigates the in vivo effects on energy homeostasis of a 15 nM MC4R antagonist SKY2-23-7, Ac-Trp-DPhe(p-I)-Arg-Trp-NH2, that is a 3700 nM melanocortin-3 receptor (MC3R) antagonist with minimal MC3R and MC4R agonist activity. When monitoring both male and female mice in TSE metabolic cages, sex-specific responses were observed in food intake, respiratory exchange ratio (RER), and energy expenditure. A 7.5 nmol dose of SKY2-23-7 increased food intake, increased RER, and trended toward decreasing energy expenditure in male mice. However, this compound had minimal effect on female mice's food intake and RER at the 7.5 nmol dose. A 2.5 nmol dose of SKY2-23-7 significantly increased female food intake, RER, and energy expenditure while having a minimal effect on male mice at this dose. The observed sex differences of SKY2-23-7 administration result in the discovery of a novel chemical probe for elucidating the molecular mechanisms of the sexual dimorphism present within the melanocortin pathway. To further explore the melanocortin sexual dimorphism, hypothalamic gene expression was examined. The mRNA expression of the MC3R and proopiomelanocortin (POMC) were not significantly different between sexes. However, the expression of agouti-related peptide (AGRP) was significantly higher in female mice which may be a possible mechanism for the sex-specific effects observed with SKY2-23-7.

Indexed as

AnimalsEatingEnergy MetabolismFemaleHumansMaleMiceMice, Inbred C57BLOligopeptidesPeptide FragmentsPeptide YYPerilipin-2Pro-OpiomelanocortinReceptor, Melanocortin, Type 3Receptor, Melanocortin, Type 4Sex FactorsOligopeptidesPeptide FragmentsPeptide YYpeptide YY (3-36)Perilipin-2Pro-OpiomelanocortinReceptor, Melanocortin, Type 3Receptor, Melanocortin, Type 4SKY-2-23-7gender differencesgene expressionGPCRhypothalamusMelanotropinRT-PCRsexsexual dimorphismTSE cagesα-MSH

Identifiers

PMID27385405
PMCPMC5687811
OpenAlexW2461929907

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.